You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)


✉ Email this page to a colleague

« Back to Dashboard


CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)

Docket ⤷  Sign Up Date Filed 2017-09-06
Court District Court, D. New Jersey Date Terminated 2019-09-05
Cause 15:1126 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand None Referred To Leda Dunn Wettre
Parties LOTUS PHARMACEUTICAL CO., LTD.
Patents 6,045,501; 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,765,106; 7,765,107; 7,855,217; 7,895,059; 7,968,569; 8,112,290; 8,315,886; 8,404,717; 8,457,988; 8,530,498; 8,589,182; 8,626,531; 8,645,160; 8,648,095; 8,731,963; 9,056,120; 9,101,621; 9,101,622
Attorneys AARON SCOTT ECKENTHAL; BRIAN JOHN FORSATZ; CHARLES MICHAEL LIZZA; DAVID LEIGH MOSES; FRANK CHARLES CALVOSA; GARRETT E. BROWN , JR.; SARAH ANN SULLIVAN; TEDD WILLIAM VAN BUSKIRK; WILLIAM C. BATON; WILLIAM L. MENTLIK
Firms Lerner, David, Littenberg, Krumholz & Mentlik, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .
Biologic Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The biologic drugs covered by the patents cited in this case are ⤷  Sign Up and ⤷  Sign Up .

Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2017-09-06 1 expiration of United States Patent Nos. 5,635,517 (“the ʼ517 patent”); 6,315,720 (“the ʼ720 … 35 PageID: 2 patent”); 6,561,977 (“the ʼ977 patent”); 6,755,784 (“the ʼ784 patent”); 7,189,740 (“the…“the ʼ740 patent”); 7,465,800 (“the ʼ800 patent”); 7,855,217 (“the ʼ217 patent”); 7,968,569 (“the ʼ569…ʼ569 patent”); 8,315,886 (“the ʼ886 patent”); 8,404,717 (“the ʼ717 patent”); 8,530,498 (“the ʼ498 patent…,531 (“the ʼ531 patent”); 8,648,095 (“the ʼ095 patent”); 9,056,120 (“the ʼ120 patent”); 9,101,621 (“the External link to document
2019-01-30 101 Covenant Not to Sue for Infringement of U.S. Patent No. 7,855,217 (Attachments: # 1 Certificate of Service… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-02-21 105 BIFURCATION AND STAY WITH RESPECT TO U.S. PATENT NOS. 6,315,720, 6,561,977, 6,775,784, 8,315,886 AND 8,626,531… 5 September 2019 2:17-cv-06842 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.